MENU
FMED
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

FMED stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
FMED
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for FMED with price predictions
Oct 21, 2026

FMED in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 08, 2026

FMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 32 cases where FMED's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on FMED as a result. In 46 of 56 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for FMED just turned positive on October 21, 2026. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in 27 of 32 cases over the following month. The odds of a continued upward trend are 84%.

FMED moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in 168 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for FMED crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Intuitive Surgical (NASDAQ:ISRG), Moderna (NASDAQ:MRNA), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH).

Industry description

The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.

Market Cap

The average market capitalization across the Fidelity Disruptive Medicine ETF (FMED) ETF is 40.23B. The market cap for tickers in the group ranges from 76.13M to 1.13T. LLY holds the highest valuation in this group at 1.13T. The lowest valued company is OM at 76.13M.

High and low price notable news

The average weekly price growth across all stocks in the Fidelity Disruptive Medicine ETF (FMED) ETF was 33%. For the same ETF, the average monthly price growth was 29%, and the average quarterly price growth was 278%. IRON experienced the highest price growth at 36%, while UPB experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Fidelity Disruptive Medicine ETF (FMED) ETF was -2%. For the same stocks of the ETF, the average monthly volume growth was -8% and the average quarterly volume growth was -19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 52
Price Growth Rating: 47
SMR Rating: 79
Profit Risk Rating: 83
Seasonality Score: 21 (-100 ... +100)